• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Bolt Biotherapeutics Inc.

    4/26/24 4:07:51 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLT alert in real time by email
    DEFA14A 1 2024_bolt_defa14a.htm DEFA14A DEFA14A

     

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material Under §240.14a-12

     

    Bolt Biotherapeutics, Inc.

     

    (Name of Registrant as Specified In Its Charter)

     

    Not applicable

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials.

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     


     

     

    img81355095_0.jpg 

     

    Scan QR for digital voting Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved styleIPC This proxy is being solicited on behalf of the Board of Directors The undersigned hereby appoints Randall C. Schatzman, Ph.D. and William P. Quinn (the "Named Proxies"), and each or either of them, as the true and lawful attorneys of the undersigned, with full power of substitution and revocation, and authorizes them, and each of them, to vote all the shares of capital stock of Bolt Biotherapeutics, Inc., which the undersigned is entitled to vote at said meeting and any adjournment thereof upon the matters specified and upon such other matters as may be properly brought before the meeting or any adjournment thereof, conferring authority upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given. THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED IDENTICAL TO THE BOARD OF DIRECTORS' RECOMMENDATION. This proxy, when properly executed, will be voted in the manner directed herein. In their discretion, the Named Proxies are authorized to vote upon such other matters that may properly come before the meeting or any adjournment or postponement thereof. You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors’ recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and return this card. PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE Bolt Biotherapeutics, Inc. Annual Meeting of Stockholders For Stockholders of record as of April 15, 2024 Wednesday, June 12, 2024 11:00 AM, Pacific Time Annual Meeting to be held live via the Internet - please visit www.proxydocs.com/BOLT for more details. C/O TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903 Internet: www.proxydocs.com/BOLT • Cast your vote online • Have your Proxy Card ready • Follow the simple instructions to record your vote Phone: 1-855-773-1625 • Use any touch-tone telephone • Have your Proxy Card ready • Follow the simple recorded instructions Mail: • Mark, sign and date your Proxy Card • Fold and return your Proxy Card in the postage-paid envelope provided Virtual: You must register to attend the meeting online and/or participate at www.proxydocs.com/BOLT YOUR VOTE IS IMPORTANT! PLEASE VOTE BY: 11:00 AM, Pacific Time, June 12, 2024. Have your ballot ready and please use one of the methods below for easy voting: Your vote matters! Have the 12 digit control number located in the box above available when you access the website and follow the instructions. Your control number

     

     


     

     

    img81355095_1.jpg 

     

    Bolt Biotherapeutics, Inc. Annual Meeting of Stockholders Please make your marks like this: PROPOSAL YOUR VOTE BOARD OF DIRECTORS RECOMMENDS 1. To elect each of the Board's two nominees as a Class III director to serve until the 2027 Annual Meeting of Stockholders. FOR WITHHOLD 1.01 Kathleen LaPorte #P2# #P2# FOR 1.02 Nicole Onetto, M.D #P3# #P3# FOR FOR AGAINST ABSTAIN 2. To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2024. #P4# #P4# #P4# FOR Proposal_Page - VIFL You must register to attend the meeting online and/or participate at www.proxydocs.com/BOLT Authorized Signatures - Must be completed for your instructions to be executed. Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing the Proxy/Vote Form. Signature (and Title if applicable) Date Signature (if held jointly) Date THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR PROPOSALS 1 AND 2

     

     


    Get the next $BOLT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BOLT

    DatePrice TargetRatingAnalyst
    10/20/2025$7.00Buy
    H.C. Wainwright
    1/6/2022$45.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    1/6/2022Overweight → Equal-Weight
    Morgan Stanley
    11/10/2021$35.00 → $33.00Outperform
    SVB Leerink
    8/16/2021$34.00 → $35.00Outperform
    SVB Leerink
    More analyst ratings

    $BOLT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Bolt Biotherapeutics Inc.

    SCHEDULE 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    11/14/25 4:17:03 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Bolt Biotherapeutics Inc.

    SCHEDULE 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    11/14/25 4:15:19 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Bolt Biotherapeutics Inc.

    10-Q - Bolt Biotherapeutics, Inc. (0001641281) (Filer)

    11/12/25 4:08:06 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:38 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 10% to 1,415 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah was granted 23,000 shares and bought $686 worth of shares (125 units at $5.49), increasing direct ownership by 2,827% to 23,943 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    10/24/25 7:19:22 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BOLT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BOLT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    President, CEO and CFO Quinn William P. bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 6% to 2,313 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:38 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Operating Officer Yonehiro Grant

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:18 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Senior VP, Finance and PAO Nemec Sarah bought $576 worth of shares (125 units at $4.61), increasing direct ownership by 10% to 1,415 units (SEC Form 4)

    4 - Bolt Biotherapeutics, Inc. (0001641281) (Issuer)

    2/4/26 4:32:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

    Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026  Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. "In the third quarter, we focused on developing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline. We are actively enrolling patients with gastric and gastroesophageal cancer in the

    11/12/25 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

    Initial clinical data for BDC-4182 Phase 1 dose escalation study now expected in 3Q 2026Company is implementing a 50% workforce reduction to extend cash runway into 2027 REDWOOD CITY, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced an update on the ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, a clinically validated target in oncology. A strong immune response was observed at the initial dose levels and the Company is in the process of modifying the clinical tr

    10/1/25 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline," said Willie Quinn, President and Chief Executive Officer. "We are now conducting a Phase 1

    8/14/25 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Bolt Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Bolt Biotherapeutics with a rating of Buy and set a new price target of $7.00

    10/20/25 8:44:35 AM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight and set a new price target of $11.00 from $45.00 previously

    1/6/22 9:46:37 AM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics downgraded by Morgan Stanley

    Morgan Stanley downgraded Bolt Biotherapeutics from Overweight to Equal-Weight

    1/6/22 7:59:47 AM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Financials

    Live finance-specific insights

    View All

    Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

    Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. "In the second quarter we focused on advancing BDC-4182, the first next-generation Boltbody™ ISAC in our pipeline," said Willie Quinn, President and Chief Executive Officer. "We are now conducting a Phase 1

    8/14/25 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

    Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET REDWOOD CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will host a key opinion leader (KOL) conference call and webcast featuring Ecaterina Dumbrava, M.D., associate professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center and investigator on the Phase 1 dose-escalation clinical study of BDC-3042, on Monday, May 12, 2025 at 2:30 p.m. PT / 5:30 p.m. ET. Dr. Dumbrava will discuss the results from the Phase 1 dose-escalat

    5/8/25 8:00:00 AM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team

    Refocusing pipeline to Phase 1 Dectin-2 agonist antibody BDC-3042 and next-generation Boltbody™ ISAC platform including new clinical candidate BDC- 4182 targeting Claudin 18.2Bolt to cease further development of trastuzumab imbotolimod (BDC-1001) and reduce workforce by approximately 50%Willie Quinn, Chief Financial Officer, is being appointed as Chief Executive Officer; Randall Schatzman moving to an advisory roleDawn Colburn, Pharm.D., is being promoted to Senior Vice President of Clinical Development to oversee all clinical activities; Edith Perez moving to an advisory roleCash balance of $112.8 million now expected to fund the Company into second half 2026, including generation of clinic

    5/14/24 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc.

    SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    11/14/24 4:19:06 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

    SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    2/14/24 4:57:08 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Bolt Biotherapeutics Inc. (Amendment)

    SC 13G/A - Bolt Biotherapeutics, Inc. (0001641281) (Subject)

    2/14/24 4:00:25 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLT
    Leadership Updates

    Live Leadership Updates

    View All

    Bolt Biotherapeutics Announces Changes to its Board of Directors

    REDWOOD CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Jakob Dupont, M.D., to its Board of Directors. Dr. Dupont brings more than two decades of experience in the field of oncology and immuno-oncology. With the appointment of Dr. Dupont, Executive Partner at Sofinnova Investments, Dr. Jim Healy, M.D., Ph.D., also at Sofinnova, will be stepping down as Lead Independent Director. In addition, Frank D. Lee will be departing the Board and Brian O'Callaghan, CEO of Deep Genomics, will be assuming the role of Chair. "Ja

    9/4/24 4:05:00 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pacira Appoints Frank D. Lee as Chief Executive Officer

    -- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r

    12/21/23 7:30:00 AM ET
    $BOLT
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bolt Biotherapeutics Appoints Laura Berner to Board of Directors

    REDWOOD CITY, Calif., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (NASDAQ:BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced the appointment of Laura Berner to its Board of Directors effective Dec. 14, 2022. "Laura is an accomplished biopharmaceutical executive with impressive corporate leadership, operations, and business development experience," said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. "As we continue to advance our immuno-oncology pipeline programs in the clinic, Laura brings important strategic perspective from leading and executing more than 50 transact

    12/14/22 4:43:15 PM ET
    $BOLT
    Biotechnology: Pharmaceutical Preparations
    Health Care